What We're Reading: Page 87
Industry reads hand-picked by our editors
May 26, 2023
-
BioCentury
Default could shutter FDA reviews
-
In The Pipeline
AI and the Hard Stuff
-
Evaluate Vantage
Asco 2023 – Regeneron nips at Bristol’s heels in Lag3
-
CNBC
FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults
May 25, 2023
-
The Economist
Clinical trials are too slow and too costly—here is how to fix them
-
The Washington Post
Medical use of ketamine is surging. So are illicit forms of the drug.
-
CNN
Experimental drugs aim to surpass weight-loss stars like Ozempic and Wegovy
-
PharmaVoice
From FTC to SCOTUS, Amgen’s woes are potential ‘game changers’ for the industry
Previous
